Search Results
Supply Chain Innovation Delivers More Nimble, Efficient Solutions
The COVID-19 pandemic exposed the fragility of the global supply chain. Want to renovate your house? Expect a 6-month delay in building materials. Buying a smartphone? With an astounding 2,000 components in many of the latest models, just one missing element creates a bottleneck in manufacturing and represents billions of dollars in lost revenue. Similar supply chain threats exist in the medtech industry.
Baxter Announces CFO Transition
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the departure of executive vice president and chief financial officer (CFO) Jay Saccaro. Mr. Saccaro will leave Baxter at the end of May after 21 cumulative years with the company, including the past eight as CFO, to join a company in the healthcare industry.
Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to Advent International and Warburg Pincus for $4.25 Billion
Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced that it has signed a definitive agreement to divest its BioPharma Solutions (“BPS”) business to Advent International (“Advent”), one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor.
Baxter Names Chris Toth CEO of Proposed Kidney Care Spinoff
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has selected Chris Toth to be chief executive officer (CEO) of the company’s planned spinoff of its Renal Care and Acute Therapies businesses. Until the spinoff, which remains subject to satisfaction of customary conditions and is currently expected to occur by July 2024 or earlier, Mr.
Baxter Declares Quarterly Dividend
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on July 3, 2023, to shareholders of record as of June 2, 2023. The indicated annual dividend rate is $1.16 per share of common stock. About Baxter
Baxter Reports First-Quarter 2023 Results
Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023.
A Teacher at Heart
Heart disease runs in Kim’s family. When she lost both parents, she made it her mission to share her knowledge about cardiac monitoring with technicians and clinicians to identify potential issues early.
Baxter to Present at BofA Securities 2023 Health Care Conference
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through November 5, 2023. About Baxter
Baxter to Host First-Quarter 2023 Financial Results Conference Call For Investors
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2023 financial results on Thursday, April 27, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/WhpPxesO to pre-register for the call and receive the call information.
Baxter Launches Zosyn Premix In US
Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced the U.S. launch of ZOSYN (piperacillin and tazobactam) Injection. Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers.